Business Wire

MN-KINDEVA-DRUG-DELIVERY

Share
Denis Johnson Joins Kindeva Drug Delivery as Chief Operating Officer to Lead Global Operations

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced that Denis Johnson has joined the company as its new Chief Operating Officer (COO). Denis joins Kindeva to lead global operations for all Kindeva’s state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418293964/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Denis Johnson joins Kindeva Drug Delivery as Chief Operating Officer, leading Kindeva’s state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K. (Photo: Business Wire)

As COO, he will be dedicated to global operations, but notably facilitating the expansion and opening of Kindeva’s new aseptic injectable fill-finish site in Bridgeton, Missouri, opening this year, as well as the company’s focus on bringing green propellants to commercial combination product manufacturing for more eco-friendly inhalers, with Kindeva being the only CDMO capable of filling inhalers with lower Global Warming Potential (GWP) 152a propellant. Denis has extensive life sciences leadership and manufacturing experience to bring to this role. Most recently, he served as Head of Global Manufacturing and Technical Operations at Biogen and held several leadership roles at Catalent, Boston Scientific, Teradyne, and Johnson & Johnson. He started his career in the U.S. Army managing logistics and operations.

“Denis’ extensive experience in the CDMO space and track record of driving operational excellence will be invaluable as Kindeva continues to expand and innovate in the drug-delivery space,” said Kindeva CEO Milton Boyer. “His strong leadership skills and deep understanding of the market will support Kindeva specifically in working toward introducing the first 152a commercial green propellant line to the market — clinical supply is already available and by 2025, we plan to introduce some of the first-ever products using this alternative propellant to the market. Additionally, Denis will focus on optimizing manufacturing processes, enhancing operational efficiencies, ensuring the highest level of quality and compliance across all facilities, and more.”

“Kindeva’s commitment to more patient-centric, sustainable drug delivery systems as well as continued growth, especially over the past year, is exciting,” Denis said. “I’m excited to join the Kindeva team to drive continued operational excellence and implement strategies that ensure the timely delivery of life-changing medications to patients worldwide.”

About Kindeva Drug Delivery

Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418293964/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB adds AI-driven geosteering to its autonomous drilling solutions to achieve more efficient and productive wells9.12.2024 14:29:00 CET | Press release

Intelligent closed-loop drilling system dynamically responds to subsurface geological informationKeeps well trajectory in the “sweet spot” of the reservoir for maximum productionImproves efficiency — minimizing the carbon footprint of drilling operations Global energy technology company SLB (NYSE: SLB) introduces Neuro™ autonomous geosteering, which dynamically responds to subsurface complexities to drill more efficient, higher-performing wells, while reducing the carbon footprint of the drilling operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241127402342/en/ Using AI, Neuro geosteering integrates and interprets complex real-time subsurface information to autonomously guide the drill bit through the most productive layer or “sweet spot” of the reservoir. (Photo: Business Wire) Using artificial intelligence (AI), Neuro geosteering integrates and interprets complex real-time subsurface information to autonomously g

DeepGreenX Group and Hues Capital Launch $10 Billion USD Fund to Accelerate AI, Green Energy, and Computing Power9.12.2024 13:00:00 CET | Press release

New DXG-Hues Fund will target innovative enterprises and solutions in these transformative ecosystems worldwide DeepGreenX Group Inc. (“DeepGreenX,” “DXG,” or the “Company”), an AI-enabled green energy and technology company, and Hues Capital (“Hues”), a leading capital provider enabling financial technology ecosystems, AI, and green energy enterprises, jointly announced the formation of a new $10 billion USD fund (the “Fund”) to drive global advancements in AI, green energy, and computing power and accelerate sustainability initiatives worldwide. DeepGreenX and Hues will each hold a 50% stake and act as co-general partners in the $10 billion USD DXG-Hues parent fund, which will be based in the EU and comprise two $5 billion USD sub-funds: the DXG-Hues AI Computing Infrastructure Fund and the DXG-Hues AI Energy Fund. The former will focus on global investments in AI computing power and green energy infrastructure projects, while the latter will target emerging enterprises in the fields

Kinaxis Offers a Solution to Streamline Bel’s Supply Chain9.12.2024 13:00:00 CET | Press release

Bel Group, a major player in food through dairy, fruit and plant-based healthier eating portions, with iconic international brands such as The Laughing Cow®, Kiri®, Babybel®, Boursin®, Nurishh®, or GoGo squeeZ®, has partnered with Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, and its solution extension partner 4flow, to transform its supply chain operations from demand to distribution. As part of its strategic growth and sustainability initiatives, Bel Group sought innovative solutions to boost operational performance, enhance collaboration and strengthen sustainability. Renowned for iconic brands like Boursin®, Babybel®, The Laughing Cow®, GoGo squeeZ®, the Group needed a robust, agile supply chain capable of withstanding any disruption as it continues to grow and diversify its product offerings. “Our foremost priority is delighting our customers with fresh, premium-quality products, delivered with precision and care,” said Xavier François, chief

Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax9.12.2024 12:00:00 CET | Press release

Following to the previous information on Oct. 28th. in 2024, we are excited to share our latest development status. We are pleased to announce that the data review committee (DMC) has approved the tolerability of the first three patients enrolled in the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) (NCT06382168) conducted at five US clinical sites for patients with acute myeloid leukemia (AML) who have failed/relapsed after standard VEN therapy (first-line therapy). Additionally, the bone marrow cell count in peripheral blood in all three cases was 0 (zero) within 4 (four) weeks of starting treatment, and complete remission (CR or CRi) was confirmed by subsequent bone marrow biopsy. Three more patients will be added at the current dosage regimen, and after confirmation of the tolerability, the study will move to Phase II. Complete remission has been observed in patients who have failed/relapsed after existing VEN combination therapy (first-line therapy), s

Ninjacart Startup Program Launches to Empower FoodTech and AgTech Startups in Accelerating Growth9.12.2024 11:00:00 CET | Press release

Ninjacart, India’s leading agri-tech startup has announced the launch of its Ninjacart Startup Program. This agri-tech-focused startup program aims to accelerate the growth of early-stage FoodTech and AgTech startups by providing access to cutting-edge technology, venture capital partners, financial backing, and expert business advisory. With nearly a decade of experience in transforming agricultural ecosystems, Ninjacart has collaborated with global agri-tech innovators to optimize supply chains and address distribution challenges. The Ninjacart Startup Program leverages this expertise to help startups scale faster, drive change, and lead the future of food distribution. The Ninjacart Startup Program offers four key benefits to participants: Access to Ninjacart’s Advanced Technology: Ninjacart’s industry-leading, cutting edge technology offers startups access to a focused suite of supply chain management proprietary tools to drive growth or enhance operational efficiency. Growth tools

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye